Sectoral Asset Management Inc. Substantial Investments in Biotech Stocks During Q2 2026

As of June 30, 2026, Sectoral Asset Management Inc. has shown notable activity in its portfolio. The investment firm primarily focuses on the Healthcare sector, which currently accounts for a dominant 96.52% allocation to its total assets of $119.8 million.

The most significant change observed this quarter involves substantial increases in holdings across several biotechnology companies. Notably, Biontech SE (BNTX) saw its position grow by 88.91%, adding nearly 200,000 shares to the portfolio.

Dexcom Inc. (DXCM), a leader in continuous glucose monitoring technology, also experienced a massive increase of 118.48% in its share count during this period.

Furthermore, Arcus Biosciences (RCUS), involved in developing antibody drug conjugates, added over 65,000 shares, representing a more than doubling of its position.

And Summit Therapeutics (SMMT) reported the highest percentage increase at 216.28%, adding approximately 150,000 shares to its existing stake in this oncology-focused biotech.

Irithm Holdings Inc. (IRTC) also saw a doubling of its position with an increase of 100%. These significant purchases suggest confidence in the growth potential and prospects within certain segments of the biotechnology industry.

In contrast, while maintaining a strong bias towards Healthcare, there were exits or reductions from smaller positions. For instance, Ars Pharmaceuticals (SPRY) experienced a nearly 62% reduction in its position this quarter.

The overall portfolio turnover rate is high, reflecting active management within the sector. This indicates that Sectoral Asset Management Inc. continues to strategically allocate capital towards promising Healthcare and biotech opportunities while managing less significant positions as needed.